Article Text

PDF
Frequent expression of fibroblast growth factor-23 (FGF23) mRNA in aneurysmal bone cysts and chondromyxoid fibromas
  1. Rondell Graham,
  2. Smita Krishnamurthy,
  3. Andre Oliveira,
  4. Carrie Inwards,
  5. Andrew L Folpe
  1. Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Professor Andrew L Folpe, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA; folpe.andrew{at}mayo.edu

Abstract

Osteomalacia has multiple aetiologies including the least common, tumour-induced osteomalacia (TIO). Recently, most cases of TIO have been confirmed to be due to phosphaturic mesenchymal tumour of mixed connective tissue type (PMTMCT). Most cases of TIO are the result of production of the fibroblast growth factor-23 (FGF-23) by the tumour. The authors recently showed reverse transcriptase PCR (RT-PCR) for FGF-23 to be valuable in the diagnosis of PMTMCT. However, the authors also noted FGF-23 expression in some cases of aneurysmal bone cyst (ABC) and chondromyxoid fibroma (CMF). For the present study, the authors studied FGF-23 expression by RT-PCR in 19 cases of ABC and eight cases of CMF, all with typical clinical and radiographic features and without evidence of TIO. Seven of 16 (44%) ABC and two of seven (29%) CMF were positive for FGF-23. These results confirm that ABC and CMF not uncommonly express FGF-23. These results strongly suggest caution and careful integration with all other clinical and radiographic data in the use of FGF-23 RT-PCR for the diagnosis of PMTMCT.

  • Phosphaturic mesenchymal tumour
  • FGF-23
  • aneurysmal bone cyst
  • chondromyxoid fibroma
  • RT-PCR
  • rhabdomyosarcoma
  • kaposi's sarcoma
  • molecular pathology
  • oncogenes
  • soft tissue tumours
  • sarcomas
  • neoplasms
  • aeromonas

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval Ethics approval was provided by Mayo Clinic IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.